KOL Views: What will Opdivo/Yervoy need to show in CM-227 to change practice patterns in 1L NSCLC?

Bristol-Myers Squibb reported top-line findings from the Phase III CheckMate-227 trial showing that Opdivo (nivolumab) plus Yervoy (ipilimumab) significantly improved progression-free survival (PFS) in front-line non-small-cell lung cancer (NSCLC), though incomplete biomarker data and immature overall survival results leave a lot of questions unanswered. (See ViewPoints: Bristol-Myers Squibb hedges its bets on a new biomarker in lung cancer.)

To provide FirstWord readers with rapid feedback on the impact of CheckMate-227, we are hosting an expert call with a key opinion leader (KOL) later this week.

Key topics that will be discussed during the call include, among other things… most important takeaways from top-line CheckMate-227 readout; are you surprised by any of the preliminary findings; what are the biggest question marks; thoughts on use and/or relevance of biomarkers like PD-L1 and tumour mutation burden (TMB) in light of CheckMate-227; level of concern about Opdivo/Yervoy’s safety profile; what would it need to show on PFS and/or overall survival in order to change practice patterns?

Ask the expert!

Furthermore, we invite FirstWord Pharma readers to submit their own questions for consideration. Please click here to do so. We can't guarantee that all questions submitted will be asked due to time constraints, but we will do our utmost to cover the important issues relating to the evolving treatment paradigm in front-line NSCLC.

We endeavour to provide feedback from KOLs as quickly as possible. Interview content will be published for FirstWord Pharma PLUS subscribers to read. To be notified when the interview content is available please click here.

To ensure access to all KOL Views content, click here to upgrade your FirstWord Pharma service or contact us to discuss your market intelligence needs.

As always, FirstWord would very much like to receive your feedback and suggestions.

To read more KOL Views articles, click here.